Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FAM148C CRISPR Activation Plasmid (h): sc-414279-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FAM148C CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- FAM148C CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by FAM148C CRISPR Activation Plasmid (h) and FAM148C CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the C2CD4C transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FAM148C Antibody (F-10): sc-515089
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FAM148C CRISPR Activation Plasmid (h) | sc-414279-ACT | 20 µg | $397.00 |
Human C2CD4C encodes FAM148C, a putative C2 domain–containing protein implicated in calcium-dependent membrane-associated processes and intracellular signaling. Although its molecular partners remain incompletely defined, expression and genetic association studies link C2CD4C to endocrine and metabolic regulation, including pancreatic islet biology and insulin secretion–related pathways. Variation near C2CD4C has been associated with susceptibility to type 2 diabetes and related cardiometabolic traits, supporting its use in studies of gene regulation, stimulus-secretion coupling, and metabolic cell state transitions. Modulating FAM148C levels can help dissect how calcium-responsive signaling nodes influence transcriptional programs in disease-relevant cell types.
FAM148C CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous C2CD4C expression without altering the underlying DNA sequence.
FAM148C CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the C2CD4C locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the C2CD4C transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous FAM148C expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native C2CD4C locus and enabling the study of FAM148C-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of FAM148C pathway restoration in tumor cells with silenced or reduced C2CD4C expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.